Abstracts Archive - Page 479 of 1683 - ATC Abstracts

2020 American Transplant Congress
Liver Transplantation for Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis of Survival Rates
I. A. Ziogas¹, K. P. Economopoulos², M. H. Hayat¹, L. K. Matsuoka¹, M. I. Montenovo¹, M. Izzy¹, S. P. Alexopoulos¹
¹Vanderbilt University Medical Center, Nashville, TN, ²Duke University Medical Center, Durham, NC
*Purpose: Liver transplant (LT) accompanied by neoadjuvant chemoradiation has emerged as the only curative option for unresectable cholangiocarcinoma (CCA). Although numerous centers have published their…
2020 American Transplant Congress
Cirrhosis-Driven Immune Dysfunction is Associated with Poor Response to DEB-TACE and Waitlist Dropout in Hepatocellular Carcinoma Patients While Awaiting Liver Transplantation
K. Nunez, T. Sandow, M. Hibino, A. Cohen, P. Thevenot
Ochsner Health System, New Orleans, LA
*Purpose: Hepatocellular carcinoma (HCC) recurrence after transplantation is associated with higher tumor grade on explant, failure to respond to DEB-TACE, and pretreatment lymphopenia. We prospectively…
2020 American Transplant Congress
Simultaneous Liver and Kidney Transplant Outcomes after “Safety Net” Policy Change
D. Keys¹, T. Leventhal¹, S. Jackson¹, S. Riad¹, R. Spong¹, A. Matas¹, J. Rao²
¹University of Minnesota, Minneapolis, MN, ²Surgery, University of Minnesota, Minneapolis, MN
*Purpose: Criteria for listing for Simultaneous Liver and Kidney (SLK) transplant changed on August 10, 2017. These changes were implemented to standardize the criteria for…
2020 American Transplant Congress
Predictors of Estimated GFR and Recurrent Chronic Kidney Disease (CKD) after Simultaneous Liver and Kidney Transplantation (SLKT): Results from the US Multicenter SKLT Consortium
P. Sharma¹, Z. Sui¹, M. Zhang¹, J. Magee¹, P. Barman², Y. Patel³, K. Walters⁴, S. Biggins⁵, A. Schluger⁶, G. Cullaro⁷, R. Wong⁸, J. Lai⁸, J. Jo⁹, J. Sinha⁹, L. VanWagner⁹, E. Verna⁷
¹Michigan Medicine, Ann Arbor, MI, ²UCSD, San Diego, CA, ³Duke, Durham, NC, ⁴UCLA, LA, CA, ⁵University of Washington, Seattle, WA, ⁶Westchester Medical Center, Weschester, NY, ⁷Columbia, New York, NY, ⁸UCSF, San Francisco, CA, ⁹Northwestern, Chicago, IL
*Purpose: SLKT is a life-saving intervention for patients with decompensated cirrhosis and concomitant end stage renal disease, irreversible acute kidney injury and select inherited metabolic…
2020 American Transplant Congress
Depletional Induction Improves Kidney Graft and Patient Survival in Recipients with a Previous Liver Transplant in the United States
S. M. Riad¹, N. Lim¹, S. Jackson², A. Matas³, J. Lake¹
¹Medicine, University of Minnesota, Minneapolis, MN, ²Fairview Health Services, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN
*Purpose: Induction choices for kidney-after-liver transplant recipients are variable. We examined the impact of kidney induction types on kidney graft and patient survival in liver…
2020 American Transplant Congress
Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells
M. Ohira¹, R. Hotta¹, Y. Imaoka¹, K. Sato¹, N. Tanimine¹, H. Tahara¹, K. Ide¹, T. Kobayashi¹, Y. Tanaka¹, A. Tzakis², S. Nishida², H. Ohdan¹
¹Hiroshima University, Hiroshima, Japan, ²University of Miami, Miami, FL
*Purpose: Development of an effective adjuvant therapy to prevent HCC recurrence after liver transplantation (LT) is an important medical requirement. Immunosuppressive regimens currently used after…
2020 American Transplant Congress
Clinical Significance of T Cell and B Cell Epitope Prediction as a Risk Factor of De Novo DSA Production after Kidney Transplantation
T. Kobayashi¹, K. Iwasaki¹, T. Tomosugi², Y. Miwa¹, M. Niemann³, E. Spierings⁴, K. Horimi¹, Y. Matsuoka¹, A. Takeda², N. Goto², S. Narumi², Y. Watarai²
¹Aichi Medical University School of Medicine, Nagakute, Japan, ²Nagoya Daini Red Cross Hospital, Nagoya, Japan, ³PIRCHE AG, Berlin, Germany, ⁴UMC Utrecht, Utrecht, Netherlands
*Purpose: Chronic antibody-mediated rejection caused by de novo DSA (dnDSA) is a major cause of graft failure. Risk prediction of dnDSA would be important for…
2020 American Transplant Congress
C-Reactive Protein 1-Year Post-Transplant is Associated with Future Development of Coronary Artery Vasculopathy and Rejection in a Pediatric Heart Transplant Cohort
H. J. Tadros, A. H. Bashir, F. J. Fricker, B. A. Pietra, D. Gupta
Congenital Heart Center/Pediatrics, University of Florida, Gainesville, FL
*Purpose: Coronary artery vasculopathy (CAV) is one of the leading causes of mortality beyond 3y post-transplant (OHT). Multiple risk factors are associated with development of…
2020 American Transplant Congress
High-Risk Antibodies Pre-Transplant Impacts Outcome after Heart Transplantation
J. A. Kobashigawa, M. Kittleson, J. Patel, D. Chang, E. Kransdorf, D. Geft, K. Nishihara, A. Shen, L. Czer, F. Esmailian
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Pre-transplant circulating antibodies (Abs) are known to impact outcome after heart transplantation (HTx). Abs can now be detected by single-bead assay but also characterized…
2020 American Transplant Congress
Graft Survival after Liver Transplantation for Patients with Cholangiocarcinoma
I. A. Ziogas, L. A. Hickman, L. K. Matsuoka, M. I. Montenovo, M. Izzy, S. A. Rega, I. D. Feurer, S. P. Alexopoulos
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Liver transplantation (LT) with neoadjuvant chemoradiation is increasingly utilized for the treatment for unresectable cholangiocarcinoma (CCA), however, post-LT graft survival is not well described.…